We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL) Antibodies|
|Epitope||AA 556-906 Alternatives|
|Conjugate||This CBL antibody is un-conjugated Alternatives|
Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-CBL AntibodyTarget Details CBL Application Details Handling Images
|Purpose||Rabbit IgG polyclonal antibody for E3 ubiquitin-protein ligase CBL(CBL) detection. Tested with WB in Human.|
|Cross-Reactivity (Details)||No cross reactivity with other proteins.|
Rabbit IgG polyclonal antibody for E3 ubiquitin-protein ligase CBL(CBL) detection. Tested with WB in Human.
Gene Name: Cbl proto-oncogene, E3 ubiquitin protein ligase
Protein Name: E3 ubiquitin-protein ligase CBL
|Purification||Immunogen affinity purified.|
|Immunogen||E.coli-derived human CBL recombinant protein (Position: A556-T906). Human CBL shares 84% amino acid (aa) sequence identity with mouse CBL.|
Target Details CBLProduct Details anti-CBL Antibody Application Details Handling Images back to top
|Alternative Name||CBL (CBL Antibody Abstract)|
CBL(Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin protein ligase. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.
Synonyms: 4732447J05Rik antibody|C CBL antibody|Cas Br M (murine) ecotropic retroviral transforming sequence antibody|Cas-Br-M (murine) ecotropic retroviral transforming sequence antibody|Casitas B lineage lymphoma proto oncogene antibody|Casitas B-lineage lymphoma proto-oncogene antibody|CBL 2 antibody|cbl antibody|CBL_HUMAN antibody|CBL2 antibody|E3 ubiquitin protein ligase CBL antibody|E3 ubiquitin-protein ligase CBL antibody|Oncogene CBL2 antibody|Proto oncogene c CBL antibody|Proto-oncogene c-CBL antibody|RGD1561386 antibody|RING finger protein 55 antibody|RNF55 antibody|Signal transduction protein CBL antibody
|Research Area||Cancer, Transcription Factors, Proteolysis / Ubiquitin|
|Pathways||TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals|
Application DetailsProduct Details anti-CBL Antibody Target Details CBL Handling Images back to top
WB: Concentration: 0.1-0.5 μg/mL, Tested Species: Human, The detection limit for CBL is approximately 0.25 ng/lane under reducing conditions.
Notes: Tested Species: Species with positive results.
Other applications have not been tested. Optimal dilutions should be determined by end users.
Antibody can be supported by chemiluminescence kit ABIN921124 in WB.
|Restrictions||For Research Use only|
HandlingProduct Details anti-CBL Antibody Target Details CBL Application Details Images back to top
|Reconstitution||Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.|
|Buffer||Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.
ImagesProduct Details anti-CBL Antibody Target Details CBL Application Details Handling back to top